Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.

Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure outcomes, assessed as a composite endpoint, and improvements ...

Both primary endpoints were met. Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart ...

Tirzepatide reduced cardiovascular death or heart failure worsening by 38% in patients ... ejection fraction (HFpEF), it sharply cuts the risk of dying from a cardiovascular (CV) event or seeing ...

Data from the SUMMIT clinical trial demonstrated that tirzepatide lowered the risk of negative heart failure outcomes and enhanced symptoms and physical limitations when tested with three different ...

The study found participants in the tirzepatide group had a reduced combined risk of cardiovascular death and worsening heart failure events compared to the participants in the placebo group.

INDIANAPOLIS, Nov. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of ...